Cargando…

Suppression of angiotensin II-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide

Dysregulation of the renin-angiotensin system leads to systemic hypertension and maladaptive fibrosis in various organs. We showed recently that myocardial fibrosis and the loss of cardiac function in mice with transverse aortic constriction (TAC) could be averted by treatment with the caveolin-1 sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chinnakkannu, Panneerselvam, Reese, Charles, Gaspar, John Antony, Panneerselvam, Saraswathi, Pleasant-Jenkins, Dorea, Mukherjee, Rupak, Baicu, Catalin, Tourkina, Elena, Hoffman, Stanley, Kuppuswamy, Dhandapani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303044/
https://www.ncbi.nlm.nih.gov/pubmed/30576317
http://dx.doi.org/10.1371/journal.pone.0207844
_version_ 1783382104793415680
author Chinnakkannu, Panneerselvam
Reese, Charles
Gaspar, John Antony
Panneerselvam, Saraswathi
Pleasant-Jenkins, Dorea
Mukherjee, Rupak
Baicu, Catalin
Tourkina, Elena
Hoffman, Stanley
Kuppuswamy, Dhandapani
author_facet Chinnakkannu, Panneerselvam
Reese, Charles
Gaspar, John Antony
Panneerselvam, Saraswathi
Pleasant-Jenkins, Dorea
Mukherjee, Rupak
Baicu, Catalin
Tourkina, Elena
Hoffman, Stanley
Kuppuswamy, Dhandapani
author_sort Chinnakkannu, Panneerselvam
collection PubMed
description Dysregulation of the renin-angiotensin system leads to systemic hypertension and maladaptive fibrosis in various organs. We showed recently that myocardial fibrosis and the loss of cardiac function in mice with transverse aortic constriction (TAC) could be averted by treatment with the caveolin-1 scaffolding domain (CSD) peptide. Here, we used angiotensin II (AngII) infusion (2.1 mg/kg/day for 2 wk) in mice as a second model to confirm and extend our observations on the beneficial effects of CSD on heart and kidney disease. AngII caused cardiac hypertrophy (increased heart weight to body weight ratio (HW/BW) and cardiomyocyte cross-sectional area); fibrosis in heart and kidney (increased levels of collagen I and heat shock protein-47 (HSP47)); and vascular leakage (increased levels of IgG in heart and kidney). Echocardiograms of AngII-infused mice showed increased left ventricular posterior wall thickness (pWTh) and isovolumic relaxation time (IVRT), and decreased ejection fraction (EF), stroke volume (SV), and cardiac output (CO). CSD treatment (i.p. injections, 50 μg/mouse/day) of AngII-infused mice significantly suppressed all of these pathological changes in fibrosis, hypertrophy, vascular leakage, and ventricular function. AngII infusion increased β1 and β3 integrin levels and activated Pyk2 in both heart and kidney. These changes were also suppressed by CSD. Finally, bone marrow cell (BMC) isolated from AngII-infused mice showed hyper-migration toward SDF1. When AngII-infused mice were treated with CSD, BMC migration was reduced to the basal level observed in cells from control mice. Importantly, CSD did not affect the AngII-induced increase in blood pressure (BP), indicating that the beneficial effects of CSD were not mediated via normalization of BP. These results strongly indicate that CSD suppresses AngII-induced pathological changes in mice, suggesting that CSD can be developed as a treatment for patients with hypertension and pressure overload-induced heart failure.
format Online
Article
Text
id pubmed-6303044
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63030442019-01-08 Suppression of angiotensin II-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide Chinnakkannu, Panneerselvam Reese, Charles Gaspar, John Antony Panneerselvam, Saraswathi Pleasant-Jenkins, Dorea Mukherjee, Rupak Baicu, Catalin Tourkina, Elena Hoffman, Stanley Kuppuswamy, Dhandapani PLoS One Research Article Dysregulation of the renin-angiotensin system leads to systemic hypertension and maladaptive fibrosis in various organs. We showed recently that myocardial fibrosis and the loss of cardiac function in mice with transverse aortic constriction (TAC) could be averted by treatment with the caveolin-1 scaffolding domain (CSD) peptide. Here, we used angiotensin II (AngII) infusion (2.1 mg/kg/day for 2 wk) in mice as a second model to confirm and extend our observations on the beneficial effects of CSD on heart and kidney disease. AngII caused cardiac hypertrophy (increased heart weight to body weight ratio (HW/BW) and cardiomyocyte cross-sectional area); fibrosis in heart and kidney (increased levels of collagen I and heat shock protein-47 (HSP47)); and vascular leakage (increased levels of IgG in heart and kidney). Echocardiograms of AngII-infused mice showed increased left ventricular posterior wall thickness (pWTh) and isovolumic relaxation time (IVRT), and decreased ejection fraction (EF), stroke volume (SV), and cardiac output (CO). CSD treatment (i.p. injections, 50 μg/mouse/day) of AngII-infused mice significantly suppressed all of these pathological changes in fibrosis, hypertrophy, vascular leakage, and ventricular function. AngII infusion increased β1 and β3 integrin levels and activated Pyk2 in both heart and kidney. These changes were also suppressed by CSD. Finally, bone marrow cell (BMC) isolated from AngII-infused mice showed hyper-migration toward SDF1. When AngII-infused mice were treated with CSD, BMC migration was reduced to the basal level observed in cells from control mice. Importantly, CSD did not affect the AngII-induced increase in blood pressure (BP), indicating that the beneficial effects of CSD were not mediated via normalization of BP. These results strongly indicate that CSD suppresses AngII-induced pathological changes in mice, suggesting that CSD can be developed as a treatment for patients with hypertension and pressure overload-induced heart failure. Public Library of Science 2018-12-21 /pmc/articles/PMC6303044/ /pubmed/30576317 http://dx.doi.org/10.1371/journal.pone.0207844 Text en © 2018 Chinnakkannu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Chinnakkannu, Panneerselvam
Reese, Charles
Gaspar, John Antony
Panneerselvam, Saraswathi
Pleasant-Jenkins, Dorea
Mukherjee, Rupak
Baicu, Catalin
Tourkina, Elena
Hoffman, Stanley
Kuppuswamy, Dhandapani
Suppression of angiotensin II-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide
title Suppression of angiotensin II-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide
title_full Suppression of angiotensin II-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide
title_fullStr Suppression of angiotensin II-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide
title_full_unstemmed Suppression of angiotensin II-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide
title_short Suppression of angiotensin II-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide
title_sort suppression of angiotensin ii-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303044/
https://www.ncbi.nlm.nih.gov/pubmed/30576317
http://dx.doi.org/10.1371/journal.pone.0207844
work_keys_str_mv AT chinnakkannupanneerselvam suppressionofangiotensiniiinducedpathologicalchangesinheartandkidneybythecaveolin1scaffoldingdomainpeptide
AT reesecharles suppressionofangiotensiniiinducedpathologicalchangesinheartandkidneybythecaveolin1scaffoldingdomainpeptide
AT gasparjohnantony suppressionofangiotensiniiinducedpathologicalchangesinheartandkidneybythecaveolin1scaffoldingdomainpeptide
AT panneerselvamsaraswathi suppressionofangiotensiniiinducedpathologicalchangesinheartandkidneybythecaveolin1scaffoldingdomainpeptide
AT pleasantjenkinsdorea suppressionofangiotensiniiinducedpathologicalchangesinheartandkidneybythecaveolin1scaffoldingdomainpeptide
AT mukherjeerupak suppressionofangiotensiniiinducedpathologicalchangesinheartandkidneybythecaveolin1scaffoldingdomainpeptide
AT baicucatalin suppressionofangiotensiniiinducedpathologicalchangesinheartandkidneybythecaveolin1scaffoldingdomainpeptide
AT tourkinaelena suppressionofangiotensiniiinducedpathologicalchangesinheartandkidneybythecaveolin1scaffoldingdomainpeptide
AT hoffmanstanley suppressionofangiotensiniiinducedpathologicalchangesinheartandkidneybythecaveolin1scaffoldingdomainpeptide
AT kuppuswamydhandapani suppressionofangiotensiniiinducedpathologicalchangesinheartandkidneybythecaveolin1scaffoldingdomainpeptide